The Directors (together with their families and their family trusts and pension scheme and other arrangements) in aggregate hold 1,276,379 ordinary shares in the Company, representing 2.23% of the Company’s current issued share capital. 2.23% of the issued share capital is not in public hands. The Company has been made aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares:
| Number of ordinary shares | % of issued share capital |
| Octopus Investments Nominees Ltd | 5.89% |
| Rosetta Capital VI GP LP, on behalf of Rosetta Capital VI, LP | 5.65% |
| Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP | 5.27% |
The above information was last updated on Friday 21 July 2023.